🟢 BioXcel Therapeutics is trading 5% up today after disclosing $1.25 million in additional term loans

BioXcel Therapeutics is trading 5.07% up at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit amendment.

• The financing included a $250,000 upfront fee and reduced the minimum liquidity covenant to $250,000.
• It provided near-term financing support while highlighting ongoing liquidity pressure.
• XBI rose 2.06% during regular trading, offering a modest biotech-sector tailwind.